Microbot Medical Stock-Based Compensation Growth & History (MBOT)

Microbot Medical's stock-based compensation was $1.1M for fiscal 2025.

View full Microbot Medical company overview

Microbot Medical annual stock-based compensation history

Microbot Medical annual stock-based compensation

Fiscal yearPeriod endedStock-based compensationChangeGrowth
20252025-12-31$1.1M−$292,000−21.65%
20242024-12-31$1.3M−$45,000−3.23%
20232023-12-31$1.4M−$358,000−20.43%
20222022-12-31$1.8M$366,000+26.41%
20212021-12-31$1.4M−$551,000−28.45%
20202020-12-31$1.9M$838,000+76.25%
20192019-12-31$1.1M−$300,000−21.44%
20182018-12-31$1.4M$920,000+192.07%
20172017-12-31$479,000−$197,000−29.14%
20162016-12-31$676,000−$3.6M−84.07%
20152015-12-31$4.2M$2.2M+108.58%
20142014-12-31$2.0M−$573,772−21.99%
20132013-12-31$2.6M−$269,464−9.36%
20122012-12-31$2.9M−$382,803−11.74%
20112011-12-31$3.3M−$668,697−17.02%
20102010-12-31$3.9M−$273,636−6.51%
20092009-12-31$4.2M

Microbot Medical stock-based compensation trends

Over the last five fiscal years, Microbot Medical's stock-based compensation decreased from $1.9M to $1.1M, a change of −$880,000. The latest reported quarter, Q2 2026, shows $433,000.

About the metric

What stock-based compensation means

Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.

Calculation and source

SEC-reported stock-based compensation

TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Microbot Medical source filings ↗

Community posts

It’s quiet here.

No posts about MBOT yet. Start the conversation.

Write the first post